)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Acurx Pharmaceuticals
Acurx Pharmaceuticals (ACXP) investor relations material
Acurx Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
PATHFINDER, a 20-patient trial in multiply recurrent CDI, began enrollment September 29, ahead of the original Q4 2026 expectation; findings are intended to guide Phase 3 planning.
FDA is open to discussing the totality of PATHFINDER and IBZ-ASPIRE efficacy evidence at a pre-NDA meeting, assessing whether it can support an NDA.
Q3 net loss was $2.58 million and cash was $9.65 million at September 30, 2026; available cash is not expected to cover the next 12 months’ anticipated needs.
Financial highlights
Q3 R&D expense was $1.12 million vs. $0.43 million YoY; 9M expense was $2.53 million vs. $1.55 million, primarily reflecting recurrent CDI program costs.
Q3 G&A expense was $1.52 million vs. $1.60 million YoY; 9M G&A was $4.13 million vs. $4.92 million, mainly due to lower professional fees and legal costs.
Q3 operating expenses and operating loss were $2.63 million vs. $2.03 million; net loss was $2.58 million vs. $1.99 million.
9M operating expenses and operating loss were $6.65 million vs. $6.47 million; net loss was $6.52 million vs. $6.39 million.
Cash was $9.65 million at September 30, 2026, vs. $7.6 million at December 31, 2025.
Outlook and guidance
FDA review of PATHFINDER and IBZ-ASPIRE will assess whether combined efficacy evidence is robust enough to support an NDA; a pre-NDA discussion may follow completion of trial data.
PATHFINDER II under the LPAD pathway may be an alternative to ASPIRE; if PATHFINDER succeeds, its results with IBZ-ASPIRE could support potential acute and recurrence-prevention indications.
PATHFINDER II could enroll ~350 patients internationally over 1.5–2 years with an active comparator; VOWST is under consideration, and design and cost depend on PATHFINDER results.
Trial enrollment completion and a data update are anticipated in H2 2027, depending on enrollment pace; progression to PATHFINDER II depends on FDA review of the 20-patient data.
Ibezapolstat is Phase 3-ready for acute CDI, subject to financing; R&D spending is expected to increase substantially as development advances.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Acurx Pharmaceuticals
- Stockholders elected two directors and ratified CohnReznick LLP as FY 2026 auditor.ACXP
AGM 2026 - Registering 1.5M shares for resale, raising up to $2.8M for R&D, with dilution risk.ACXPRegistration filing
- Vote on director elections and auditor ratification at the October 2026 annual meeting.ACXPProxy filing
- Shareholders will vote virtually on director elections and auditor ratification, with robust governance and oversight.ACXPProxy filing
- Cash rose to $10.7M, net loss narrowed, but new funding is needed for ongoing clinical progress.ACXPQ2 2026
- DNA pol IIIC inhibitors offer potent, selective treatment for resistant Gram-positive infections.ACXPConference presentation
- Phase 3-ready antibiotic ibezapolstat shows high cure rates and strong market potential.ACXPStudy update presentation
- Advanced ibezapolstat trials, improved cash to $9.3M, but cash runway remains short.ACXPQ1 2026
- Up to 1.3M shares registered for resale via equity line, supporting R&D and operations.ACXPRegistration filing
Next Acurx Pharmaceuticals earnings date
Q4 202612 Mar, 2027
Acurx Pharmaceuticals
Next Acurx Pharmaceuticals earnings date
Q4 202612 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing antibiotic treatments for bacterial infections. The company's research and development efforts are primarily centered on addressing antibiotic resistance, targeting bacterial pathogens that pose a significant threat to public health. Acurx utilizes a novel approach to inhibit bacterial DNA synthesis, working to combat infections that are increasingly resistant to traditional antibiotics. Its pipeline includes various antibiotic candidates aimed at providing new therapeutic options for patients. The company is headquartered in Staten Island, New York, and its shares are listed on the NASDAQ.